Lipella Pharmaceuticals Inc. (LIPO)
OTCMKTS · Delayed Price · Currency is USD
0.5930
+0.0028 (0.47%)
Aug 25, 2025, 11:05 AM EDT

Lipella Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2020
0.470.540.450.180.260.96
Upgrade
Revenue Growth (YoY)
-7.30%19.29%144.15%-28.99%-73.03%38.42%
Upgrade
Cost of Revenue
3.893.613.042.551.460.98
Upgrade
Gross Profit
-3.42-3.08-2.59-2.36-1.2-0.01
Upgrade
Selling, General & Admin
2.1722.160.230.720.04
Upgrade
Operating Expenses
2.1722.160.230.720.04
Upgrade
Operating Income
-5.6-5.08-4.75-2.59-1.92-0.06
Upgrade
Interest Expense
---0.01-0.01-0.01-0.01
Upgrade
Interest & Investment Income
0.070.060.14000
Upgrade
Other Non Operating Income (Expenses)
----00-
Upgrade
EBT Excluding Unusual Items
-5.52-5.02-4.62-2.6-1.92-0.06
Upgrade
Other Unusual Items
----0.06-
Upgrade
Pretax Income
-5.52-5.02-4.62-2.6-1.87-0.06
Upgrade
Net Income
-5.52-5.02-4.62-2.6-1.87-0.06
Upgrade
Net Income to Common
-5.52-5.02-4.62-2.6-1.87-0.06
Upgrade
Shares Outstanding (Basic)
211100
Upgrade
Shares Outstanding (Diluted)
211100
Upgrade
Shares Change (YoY)
153.96%39.69%47.84%19.15%59.91%2.46%
Upgrade
EPS (Basic)
-2.54-4.79-6.16-5.12-4.38-0.23
Upgrade
EPS (Diluted)
-2.54-4.79-6.16-5.12-4.40-0.23
Upgrade
Free Cash Flow
-4.5-3.95-3.16-1.83-0.99-0.03
Upgrade
Free Cash Flow Per Share
-2.07-3.77-4.22-3.61-2.32-0.11
Upgrade
Gross Margin
------1.48%
Upgrade
Operating Margin
-1190.03%-947.23%-1055.56%-1406.26%-738.71%-5.91%
Upgrade
Profit Margin
-1174.13%-935.25%-1027.31%-1410.59%-719.30%-6.41%
Upgrade
Free Cash Flow Margin
-957.71%-736.59%-703.85%-994.35%-381.45%-2.97%
Upgrade
EBITDA
-5.59-5.08-4.74---
Upgrade
D&A For EBITDA
000---
Upgrade
EBIT
-5.6-5.08-4.75-2.59-1.92-0.06
Upgrade
EBIT Margin
------5.91%
Upgrade
Revenue as Reported
0.470.540.450.180.260.96
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.